Clinical and Surgical Sciences (Surgery), University of Edinburgh, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, United Kingdom.
Clin Nutr. 2011 Dec;30(6):812-21. doi: 10.1016/j.clnu.2011.05.010. Epub 2011 Jul 5.
BACKGROUND & AIMS: Objective assessment of daily physical activity (PA) by body-worn accelerometers offers potential as a novel endpoint in the clinical management of advanced cancer patients. This study aimed to assess criterion-based validity of an accelerometer-based activity monitoring system (AM-system), ActivPAL™, using two different methods.
Advanced cancer in patients and outpatients (Karnofsky Performance Status (KPS) 40-100). ActivPAL™ measurements were validated against (i) observations and (ii) energy expenditure (EE) measured by 2-week doubly-labelled water (DLW) protocol.
Absolute errors for mean time spent in different body positions (<0.1%) and number of transfers (0%) were low. Step count error was significantly higher in patients with KPS 40-60 (non-self caring) compared to KPS 70-100 (self-caring) (33 vs. 24%, p = 0.006). Post-hoc mathematical analysis demonstrated that absolute errors for the mean energy expenditure of activity (EEA) (1.4%) and mean total EE (0.4%) were low, but agreement was also low.
AM-systems provide valid estimates of body positions and transfers, but not step count, especially in non-self caring patients. ActivPAL™ can derive estimates of EE but there is considerable variability in results, which is consistent, in part, with the inaccuracy in step count. Further studies are required to assess the validity of different endpoints derived from AM-systems in advanced cancer patients.
通过佩戴在身体上的加速度计对日常体力活动(PA)进行客观评估,为晚期癌症患者的临床管理提供了一种新的终点评估方法。本研究旨在使用两种不同的方法评估基于加速度计的活动监测系统(AM 系统)ActivPAL™的基于标准的有效性。
研究对象为晚期癌症患者和门诊患者(卡氏行为状态评分(KPS)40-100 分)。ActivPAL™的测量结果通过(i)观察和(ii)通过为期 2 周的双标水(DLW)协议测量的能量消耗(EE)进行验证。
不同体位下的平均时间和转移次数的绝对误差(<0.1%和 0%)较低。KPS 40-60(非自理)的患者的步数误差明显高于 KPS 70-100(自理)的患者(33%比 24%,p = 0.006)。事后数学分析表明,活动平均能量消耗(EEA)(1.4%)和平均总 EE(0.4%)的绝对误差较低,但一致性也较低。
AM 系统提供了体位和转移的有效估计值,但不能提供步数的有效估计值,尤其是在非自理患者中。ActivPAL™可以得出 EE 的估计值,但结果存在相当大的变异性,这在一定程度上与步数的不准确性一致。需要进一步研究来评估 AM 系统衍生的不同终点在晚期癌症患者中的有效性。